BioLineRX Ltd. (BLRX.TA)

Stocks | Healthcare | Pharmaceuticals - Diversified

BLRX.TA on Tel Aviv Stock Exchange

394.90
4:58am EST

Price Change (% chg)

6.90₪ (+1.78%)

Prev Close
388.00₪

Open
395.80₪

Day's High
395.80₪

Day's Low
388.00₪

Volume
165,619

Avg. Vol
423,895

52-wk High
590.00₪

52-wk Low
93.00₪

BLRX.TA

About

BioLineRX Ltd. is an Israel-based company engaged in identifying and following the critical pathway to commercialization of therapeutic compounds. Led by Dr. Kinneret Savitsky, the Company's pre-clinical drug development program is referred to as BioLine Innovations Jerusalem (BIJ), supported by the Israeli Office of the Chief... (more)

Buy/Sell

No analyst recommendations are available for BLRX.TA.

» Full Recommendation

Overall

Beta:	0.00
Market Cap (Mil.):	₪479.17
Shares Outstanding (Mil.):	123.50
Annual Dividend:	--
Yield (%):	--

Financials

	BLRX.TA	Industry	Sector
P/E (TTM):	--	6.43	3.76
EPS (TTM):	28.07	--	--
ROI:	-118.50	5.95	2.30
ROE:	-118.52	8.98	2.82

Latest News about BLRX.TA

BiolineRX says drug helps schizophrenic cognition

TEL AVIV, Sept 23 (Reuters) - Israeli drug development company BiolineRX said on Wednesday results of a Phase 2b trial of its schizophrenia treatment BL-1020 demonstrate a positive impact on the cognitive function of patients.

23 Sep 2009

Ikaria to pay $285 mln for Bioline drug license

JERUSALEM, June 6 (Reuters) - Israeli drug development company BiolineRX said on Monday that New Jersey-based Ikaria Holdings Inc had agreed to pay $285 million for a license to develop and market its BL-1040 drug for heart attack patients.

06 Jul 2009

TEXT-BioLineRx achieves positive results in drug study

(The following was issued by Israel's BioLineRx Ltd ):

04 Feb 2008

Israel's BioLineRX explores Nasdaq listing

TEL AVIV, Oct 16 (Reuters) - Israel's BioLineRx Ltd. said on Tuesday its board of directors instructed management to investigate various alternatives for raising capital and the listing of the company's shares on Nasdaq.

16 Oct 2007

» More BLRX.TA News

Earnings vs Estimates

No consensus analysis data available.

Stocks

Healthcare

Pharmaceuticals - Diversified

Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.

NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.